Group 1 - China Resources Pharmaceutical (03320) announced a collaboration to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total committed capital for the fund [1] Group 2 - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration with its subsidiaries and Hanwei Huayou Shantou to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - The fund is expected not to be accounted as a subsidiary of the company upon establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Group 1 - The core announcement involves China Resources Pharmaceutical (03320.HK) planning to establish a fund with an expected scale of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology [1] - The company intends to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager after its establishment [1]

据了解，莱茵生物在合成生物学领域的布局可追溯至2016年，公司先后与中国科学院天津工业生物技术 研究所、江南大学等科研机构合作，深耕天然甜味剂及生物多糖的生物合成技术。目前已建立桂林莱茵 合成生物技术有限公司和成都赛迪科生物科技有限公司两大研发平台，分别聚焦天然甜味剂和生物多糖 领域。 截至2024年9月，莱茵生物已获得8项合成生物学相关专利授权，另有10项专利申请处于受理状态。其 中，2024年6月某一创新型甜叶菊RM系列产品已获得Self-GRAS认证，具备商业化条件；与江南大学陈 坚院士团队合作研发的罗汉果甜苷V全合成技术，更使公司成为业内首家跑通该技术路径的企业，为解 决传统种植模式的局限性提供了全新方案。 据了解，此次通过FDA GRAS认证的瑞鲍迪苷M2，是甜菊糖苷类甜味剂中的稀有高价值单体。相较于 市场上流行的RebD、RebM等成分，RebM2在甜味特性、口感纯净度、稳定性及溶解性等方面均具优 势，与其他甜味剂复配时能显著提升整体效果，应用场景覆盖食品、饮料、膳食补充剂等多个领域。 值得关注的是，莱茵生物采用酶转化法生产RebM2，在效率、成本和质量上形成显著竞争力，有效解决 了传统生产工艺产 ...

Core Viewpoint - China Resources Double Crane (华润双鹤) is strategically investing in synthetic biology, establishing a biopharmaceutical industry fund with a target of 500 million RMB to enhance its investment capabilities in key areas like synthetic biology and health products [2][4]. Group 1: Investment and Strategic Direction - On August 12, China Resources Double Crane announced plans to establish a biopharmaceutical industry fund with a target fundraising scale of 500 million RMB, with the company and its wholly-owned subsidiary contributing up to 87 million RMB, accounting for no more than 17.4% of the total fund [2]. - The company has identified synthetic biology as one of its strategic development directions and has established a comprehensive "R&D + pilot test + industrialization" three-tier system, including a synthetic biology industrialization platform in Hohhot [2][4]. - The establishment of the fund aims to optimize the company's strategic layout in synthetic biology and other key areas, leveraging synergies with Hohhot's industrial development to enhance investment methods in synthetic biology [2]. Group 2: Financial Performance - In the first quarter of 2025, China Resources Double Crane achieved revenue of 3.079 billion RMB and a net profit attributable to shareholders of 507 million RMB [3]. Group 3: Historical Context and Acquisitions - In 2022, China Resources Double Crane invested 500 million RMB to acquire Shenzhou Biology, establishing it as a base for synthetic biology industrialization [4]. - In 2023, the company established the China Resources Double Crane Synthetic Biology Research Institute, focusing on talent acquisition and the simultaneous construction of a pilot test base [4]. Group 4: Technological Development - The small-scale testing platform has been largely completed, focusing on core capabilities such as molecular modification, high-throughput screening, strain validation, and enzyme engineering [6]. - The company is prioritizing the construction of pilot fermentation workshops to enhance its pilot conversion capabilities [6]. Group 5: Market Positioning - Shenzhou Biology is recognized as the world's second-largest supplier of coenzyme Q10, holding a stable global market share of 30% [7]. - The chairman of the company emphasized that the focus on synthetic biology is primarily around health products, aiming to enhance the competitiveness of existing core products through synthetic biology technology [7].

Core Insights - The Fourth Synthetic Biology Innovation Competition was held in Guangming Science City, organized by the Chinese Society of Biotechnology and several local institutions, promoting the integration of education, technology, and talent [2] - The event attracted 265 teams and nearly 1,900 young talents from around the world, indicating a continuous increase in participation and influence since its inception in 2022 [2] - The competition featured seven tracks focusing on public health, industrial upgrading, and green low-carbon solutions, emphasizing originality and feasibility in synthetic biology innovations [2] Event Highlights - The event included a signing ceremony for a scholarship between Huaxi Biotechnology and Shenzhen University of Technology, aimed at encouraging outstanding students and fostering innovation and entrepreneurship [2] - A new research center for the intersection of synthetic biology and art was inaugurated during the event [2] - Various supporting activities were organized, including a roundtable discussion on "Synthetic Biology and Sustainable Development," experiential learning sessions, and a youth debate on "Creation and the Future" [3]

软骨素钠的业务拓展，未来受市场竞争格局变化、下游终端产品开发进度变 化及原有终端产品开展原料替换难度等因素影响，业务发展存在不确定性，提醒 广大投资者注意投资风险。 华熙生物科技股份有限公司（以下简称"公司"）自主研发的发酵法软骨素 钠原料（以下简称"软骨素钠"）成功通过国家药品监督管理局医疗器械技术审 评中心（CMDE）的主文档备案登记（登记号：M2025264-000），成为我国首 个实现发酵法软骨素钠合规化备案的企业。 本次完成备案的软骨素钠作为公司医药级原料的新品种，可应用于 II 类、III 类医疗器械，未来有望为高端医疗器械提供核心原料。 传统硫酸软骨素主要从动物软骨（如猪、牛、鸡、鲨鱼）中提取，存在动物 免疫原性、原料来源不可持续、提取工艺污染高等问题。下一步，公司将以发酵 法得到的软骨素钠为基础，利用合成生物学技术开发硫酸软骨素原料，应用于眼 科、骨科、医美等领域。 证券代码：688363 证券简称：华熙生物 公告编号：2025-029 华熙生物科技股份有限公司 关于发酵法软骨素钠完成医疗器械主文档登记的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者 ...

Group 1 - The article highlights a revolutionary breakthrough in genome editing technology, specifically a new programmable technique for precise manipulation of large DNA segments at the chromosomal level, which can edit DNA from thousands to millions of base pairs [1] - This new technology significantly enhances the scale and capability of manipulating eukaryotic genomes, providing new pathways for crop trait improvement and treatment of genetic diseases [1] - In the field of genetic disease treatment, this technology is expected to offer new therapeutic approaches for diseases caused by chromosomal abnormalities [1] Group 2 - The breakthrough in precise chromosomal editing technology is anticipated to accelerate the construction of artificial chromosomes, presenting important application prospects in emerging fields such as synthetic biology [1] - Relevant concept stocks in the A-share market include Xin Kai Yuan and Bei Rui Ji Yan, which are associated with this new technology [1]

北京商报讯（记者 丁宁）8月11日晚间，华熙生物（688363）发布公告称，公司自主研发的发酵法软骨 素钠原料（以下简称"软骨素钠"）成功通过国家药品监督管理局医疗器械技术审评中心的主文档备案登 记，成为我国首个实现发酵法软骨素钠合规化备案的企业。 华熙生物表示，本次完成备案的软骨素钠作为公司医药级原料的新品种，可应用于II类、III类医疗器 械，未来有望为高端医疗器械提供核心原料。 据悉，传统硫酸软骨素主要从动物软骨（如猪、牛、鸡、鲨鱼）中提取，存在动物免疫原性、原料来源 不可持续、提取工艺污染高等问题。华熙生物表示，下一步，公司将以发酵法得到的软骨素钠为基础， 利用合成生物学技术开发硫酸软骨素原料，应用于眼科、骨科、医美等领域。 ...